

Biochemical parameters in predicting postoperative complications in patients with upper GI malignancies

ABSTRACT

Aims: Postoperative complications are a major concern following surgery for upper GI malignancies. Studies have shown that high levels of preoperative inflammatory markers have a poor prognosis. However, the relationship between preoperative platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR) and postoperative complications after curative resection is unclear. This study aimed to evaluate the efficacy of PLR and NLR in predicting clinical outcomes and postoperative complications in these patients.

Study design: Single-center prospective observational study

Place and Duration of Study: Sample: Department of Surgical Gastroenterology, Tirunelveli Medical College, between January 2021 and December 2022.

Methodology: This single-center prospective study included seventy patients out of which 55 with gastric cancer underwent D2 gastrectomy and 15 with esophageal cancer underwent transhiatal esophagectomy. We evaluated the relationship between PLR and NLR and postoperative complications (\geq grade 1 Clavien-Dindo classification). Using a receiver operating characteristic curve, the area under the curve (AUC) for each parameter was calculated and the power to predict postoperative complications was compared.

Results: 35.71% patients experienced postoperative complications. The AUC values of NLR (0.825) and PLR (0.161) were higher when compared to other preoperative tests in predicting postoperative complications. The optimal cut-off for NLR was 1.71 (sensitivity 96% and specificity 84.4%) and for PLR was 0.56 (sensitivity 20% and specificity 84.4%). Patients in the high NLR group had an increased incidence of complications when compared to the low NLR group. 74% in the low PLR group experienced complications, whereas only 11.6% in the high PLR group experienced grade 1 or higher complications.

Conclusion: Both NLR and PLR may serve as valuable indicators of potential postoperative complications for patients receiving surgery for operable gastric and esophageal cancers.

Keywords: Gastric cancer, Esophageal cancer, Neutrophil-lymphocyte ratio, Platelet-lymphocyte ratio, Postoperative complications,

1. INTRODUCTION

Cancers of the upper gastrointestinal tract pose a major health risk around the world [1]. Gastric cancer and esophageal cancer are one of the leading causes of cancer-related morbidity and mortality worldwide [2,3]. Surgery in the form of gastrectomy and esophagectomy plays a central role in the management of these cancers [4,5,6]. Despite advances in surgical techniques, significant postoperative complications such as anastomotic leaks, postoperative pneumonia, intra-abdominal abscess formation, postoperative pancreatic fistula, etc. occur. This can impede recovery, prolong the length of hospital stay, increase hospital costs, delay adjuvant therapy, and compromise the quality of life in these patients [7,8]. Systemic inflammatory response parameters are associated with cancer initiation and progression in various malignancies [9,10]. These parameters have also been shown to be associated with an overall poor prognosis in patients with various GI and non-GI malignancies. [11,12,13,14,]. Parameters such as the platelet-to-lymphocyte ratio (PLR), neutrophil-to-

lymphocyte ratio(NLR), and prognostic nutritional index(PNI) are well-known predictors of poor prognosis in patients with gastric and esophageal cancers [15,16,17,18].

Moyes. et.al [19] in their study demonstrated that the presence of preoperative systemic inflammatory response itself independently predicted postoperative infectious complications in patients undergoing curative resection for colorectal cancer. Several studies have investigated the use of preoperative inflammatory markers for predicting postoperative complications in cancer patients undergoing surgery. [19,20]. These parameters will help surgeons to provide precise informed consent information and optimize perioperative management.

However, there has been limited research on the role of preoperative PLR and NLR in predicting early postoperative complications, length of ICU stay and hospital stay following curative surgery for stage I-III esophageal and gastric cancers. This study was undertaken to assess the value of preoperative PLR and NLR in predicting postoperative clinical outcomes and complications in patients undergoing curative surgery for stage I-III gastric and esophageal cancers.

2. MATERIAL AND METHODS

This was a single-center prospective study that collected data from 70 consecutive patients of operable stage I-III gastric and esophageal cancers between January 2021 and December 2022 for a period of 24 months at a tertiary care center in South Tamil Nadu, India. Detailed demographic, operative, perioperative, and biochemical data were collected. Relevant demographic data included patient age, sex, smoking and alcohol consumption, and presence of comorbidities namely diabetes mellitus, systemic hypertension, and cardiovascular disease.

The inclusion criteria were surgically operable and histologically confirmed stage I-III gastric and esophageal cancers with no evidence of inoperability; R0 resection performed without multiorgan resection; a gap of six weeks between neoadjuvant therapy and surgery; standard D2 gastrectomy or transhiatal esophagectomy performed with curative intent. Exclusion criteria were patients with poor ECOG performance status >3; ASA grade IV and V disease; gastric lymphomas and GIST; patients with hereditary cancer syndromes; patients with acute infectious and inflammatory conditions; and metastatic tumors

The institutional ethics committee approved the study (No: 20222430) and formal consent in addition to what the patients had given before hospitalization was obtained. This research complied with the principles outlined in the Helsinki Declaration of 1975, as revised in 2008.

A first-generation cephalosporin antibiotic was administered 30 minutes before surgery and thereafter every 4th hourly during surgery. Oral intake was initiated on postoperative day 3 in gastrectomy patients and postoperative day 6 in esophagectomy patients if no obvious complications were found. Percutaneous drainage or the replacement of drainage tubes was done when there were signs of inadequate drainage on computed tomography or ultrasound scans. Clinically relevant postoperative complications were defined as those of grade II or higher according to the Clavien-Dindo classification [21].

Relevant biochemical parameters including the preoperative complete blood count (including neutrophils, platelets, and lymphocytes) preferably obtained the day before surgery, were collected from the patient records.

The platelet-lymphocyte ratio and the neutrophil-lymphocyte ratio were calculated using the formulas:

$$\text{PLR} = \text{absolute lymphocyte count} / \text{absolute platelet count} \times 100.$$

$$\text{NLR} = \text{absolute neutrophil count} / \text{absolute lymphocyte count}$$

Tumor characteristics for esophageal and gastric cancers included tumor location, histological grade, and clinical TNM stage [by the TNM staging system of the American Joint Committee on Cancer (AJCC 8th ed., 2016)] [22].

These data were imported into an Excel spreadsheet (Microsoft Excel 2016, Microsoft Corporation, Redmond, WA, USA) and used for the interpretation of results.

2.1 Definition of post-operative complications

Complications occurring within the first 30 days following surgery were defined as postoperative complications and were graded using the Clavien–Dindo classification system [21]. When an anastomotic leak or hemorrhage was suspected, computed tomography (CT) was performed to confirm these complications. A postoperative pancreatic fistula was diagnosed when the concentration of amylase in the abdominal drain effluent was three times higher than the upper limit of the normal serum concentration on the third day after gastrectomy [23]. Postoperative pneumonia was diagnosed according to postoperative radiological findings, and one of the following clinical findings was required: body temperature 38 °C, new or progressive and continuous coughing and expectoration with an abnormal white blood cell count (<4000 or >12000/mm³), or positive respiratory cultures from sputum or blood [24, 25]. A diagnosis of postoperative small bowel obstruction was based on the patient's symptoms and abdominal X-ray and CT findings. Postoperative chyle leakage was defined as >200 mL per day of milky white fluid discharge with a triglyceride content of >110 mg/dL [26]. Patients with upper abdominal distension and remnant stomach fullness on radiographic imaging were diagnosed with postoperative remnant gastric stasis [27]. Postoperative cardiac arrhythmias were defined as cardiac complications.

2.1.1 Statistical analysis

A receiver operating characteristic (ROC) curve analysis was employed to calculate the area under the curve (AUC) and the sensitivity and specificity of PLR and NLR to predict postoperative complications. The optimal cut-off value for the variables was determined using the Youden index. After that, the study population was divided into two groups according to these cut-off points for each prominent variable. One group was representing those below the cut-off point, while the other group was representing those above the cutoff point.

At the final stage, categorical and continuous variables were evaluated by the Chi-square test and the Student-t-test where appropriate. In all analyses, a p-value of less than 0.05 was considered statistically significant.

All statistical analyses were performed using SPSS for Windows version 26.0.

3. RESULTS AND DISCUSSION

There were a total of 70 patients in our study out of which 55 patients were of gastric cancer and 15 patients of esophageal cancer. Only three patients of esophageal squamous cell carcinoma received neoadjuvant chemoradiation six weeks before surgery. (Table 1)

Table 1: Preoperative characteristics of patients


Variables	Number of patients
Age in years (median)	50 (35-69)
Sex	
Male	41
Female	29
Comorbidities	
Diabetes	31
Hypertension	32
Cardiac	3
Preoperative symptoms	
Pain abdomen	55
Gastric outlet obstruction	20
Dyspepsia	31
Loss of appetite/weight	42
Dysphagia	15
Fatigue	41
Habits	
Smoking	62
Alcohol	63
Previous history of surgery	17
Preoperative BMI mean	21.21(SD ±0.88)
ECOG performance status	
0	13
I	46
II	11
Palpable lump	7
Endoscopic tumor location	
Stomach	
Proximal third	19
Middle third	15
Distal third	21
Esophagus	
Proximal esophagus	0
Middle esophagus	3
Distal esophagus	12
Endoscopic biopsy	
Stomach	
Well-differentiated adenoCA	13
Moderately differentiated adenoCA	28
Poorly differentiated adenoCA	14

Esophagus	
Well-differentiated squamous cell CA	6
Moderately differentiated squamous cell CA	5
Poorly differentiated squamous cell CA	0
Well-differentiated adenoCA	4
Preoperative tumor stage	
Stomach	
I	0
IIA	22
IIB	18
IIIA	6
IIIB	6
IIIC	3
Esophagus	
I	12
IIA	2
IIB	1

AUC. The area under the curve; NLR. Neutrophil-to-lymphocyte ratio; PLR. Platelet-to-lymphocyte ratio


In our study 25(35.71%) patients developed complications. Mild complications (Clavien-Dindo grade I) were seen in 2(2.85%) patients. Major complications (Clavien-Dindo grades 2,3,4 and 5) were seen in 23(32.85%) patients. (Figure 1)

Figure 1: Bar chart showing types of complications and their frequency



When the AUC value which has the ability to predict postoperative complications, of the selected five parameters was calculated, the NLR demonstrated the highest AUC value (0.825, 95% CI 0.717-0.933) which was higher than the NLR components: neutrophil count(0.734, 95% CI 0.612-0.857) and lymphocyte count(0.158, 95% CI 0.055-0.261). (Figure 2)

Figure 2: The predictive powers of different laboratory variables were compared with the AUC values according to the postoperative complications grade ≥ 1 Clavien-Dindo classification.



Based on the analysis of the ROC curve, the NLR cut-off value was established at 1.71 with a sensitivity of 96% and a specificity of 84.4% for predicting postoperative complications. (Table 2)

Table 2: AUCs, and maximum sensitivity and specificity of the PLR and NLR with the optimal cut-off points

Results	NLR	PLR
AUC	0.825	0.161
95% CI	0.717-0.933	0.056-0.266
Youden index	0.8	0.04
Optimal cut-off	>1.71	<0.56
Sensitivity (%)	96	20
Specificity (%)	84.4	84.4

Using the cut-off point set by the ROC analysis, patients were divided into two subgroups, the high NLR group (>1.71) and the low NLR group (\leq 1.71). There were 61 patients in the high NLR group (n=61) and 9 patients in the low NLR group (n=9).39.34% of patients in the high NLR group were found to have an increased incidence of postoperative complications, whereas only 11.11% of patients in the low NLR group experienced grade 1 or higher postoperative complications according to the Clavien -Dindo classification. According to the ROC analysis the NLR had greater power in predicting postoperative complications than the other preoperative laboratory values.

The AUC value of PLR was 0.161. Through ROC curve analysis, the cut-off point for PLR in predicting complications was established at 0.56, with a sensitivity of 20% and a specificity of 84.4%. As a result, patients were split into two subgroups, the high PLR group (>0.56) and the low PLR group (\leq 0.56).There were 27 patients in the low PLR group and 43 patients in the high PLR group. Out of all the patients, those in the low PLR group had a complication rate of 74%, while only 11.6% of patients in the high PLR group experienced grade 1 or higher complications based on the Clavien-Dindo classification.(Table 3)

Table 3. Comparison of complications between two subgroups according to PLR and NLR

Item	All	High NLR	Low NLR	P value	High PLR	Low PLR	P value
Number of patients	70	61	9		43	27	
Complications (number of patients)	25	24	1	0.09	5	20	0.000
Anastomotic leak	4	4	0		4	0	
Wound infection	12	12	1		3	11	
Atelectasis	15	15	0		3	12	

Pneumothorax	1	1	0		1	0	
DGE	7	7	0		2	5	
Cardiac	1	1	0		0	1	
Reoperation	1	1	0		0	1	
Pancreatitis	0	0	0		0	0	
Abdominal abscess	0	0	0		0	0	
ICU stay (days, mean±SD)	2.95± 1.33	2.95± 1.33	None		1.75± 0.43	3.21± 1.32	0.034
Hospital stay (days, mean±SD)	9.97± 3	10.17± 3.08	8.14± 1.12	0.133	8.30± 1.19	12.7± 3.07	0.000
Mortality	2	2	0		0	1	

There has been widespread research on the relationship between systemic inflammatory mediators and solid cancers, yet the molecular mechanism behind this relationship is not completely understood [28-29]. The role of laboratory markers like C-reactive protein and albumin in systemic inflammatory response has been extensively studied. These parameters have been used to construct the Glasgow Prognostic Score to predict clinical outcomes in patients with colorectal and esophageal cancers [30-32].

Guthrie et al demonstrated the prognostic role of PLR and NLR in predicting postoperative complications in patients with colorectal cancers [33]. In another study, the role of elevated PLR and NLR for predicting overall morbidity in patients with head and neck cancer has been demonstrated [34]. In a study from the UK, Vulliamy et al. concluded that an elevated NLR can predict post-esophagectomy complications [35]. With this in mind, the role of NLR and PLR in predicting postoperative complications becomes more apparent in patients undergoing surgery for upper GI malignancies

When a patient undergoes surgical stress, there sets in a systemic inflammatory response which is characterized by an increase in the circulating neutrophils and a fall in the circulating lymphocytes (36). This manifests as fever, immunologic changes, and tissue repair [37]. A decrease in lymphocyte count leads to immunosuppression and malnutrition [38]. Wound healing is delayed in patients with malnutrition [39]. This, along with an impaired lymphocyte-mediated antibacterial immune response predisposes the host to increasing bacterial invasion and growth [40]. Lymphocytes play an important role in the management of tumor cells in the host. Lymphocytes mediate increased tumor infiltration which is associated with improved response to chemotherapy and overall prognosis [40]. An increase in neutrophil count induces tumor progression and angiogenesis by suppression of the antitumor response of lymphocytes, activated T cells, and NK cells [41]. This leads to a pro-inflammatory state compromising the cell-mediated immunity and the T lymphocyte responses of the host [42]. An increase in platelet count is associated with a pro-inflammatory state and induces potential micro-vessel thrombosis. This also delays the process of wound healing [43]. All these factors put together to increase the incidence of postoperative complications in patients with malignancies.

The NLR, a ratio of circulating neutrophils to lymphocytes represents systemic inflammation and immune response [44]. Therefore, an increase in NLR value indicates both systemic inflammation and compromised immune response resulting in an increased incidence of postoperative complications in these patients. The PLR a ratio of platelets to lymphocytes in a similar way, is also a marker of systemic inflammation and deranged immune response in the host, as suggested by Inaoka K et al [38].

In this study, the AUC value of NLR for predicting post-operative complications was 0.825, (95% CI 0.717-0.933) and the AUC value of PLR was 0.161 (95% CI 0.056-0.266). These values were greater than the AUC values of all other biochemical parameters for predicting postoperative complications. The cut-off values were calculated using the ROC curves and the Youden index, to investigate the relations of the PLR and NLR with each of the variables such as mortality, anastomotic leaks, postoperative complications, length of hospital stay, and length of ICU stay. The cut off value for NLR was 1.71 (sensitivity=96%, specificity=84.4%) and the cut off value for PLR was 0.56 (sensitivity=20% and specificity=84.4%).

Our study could credibly demonstrate a relationship between the preoperative PLR and NLR in predicting postoperative complications in patients undergoing surgery for upper GI malignancies. A high NLR and a low PLR were associated with the occurrence of complications such as mortality, anastomotic leaks, wound infections, pulmonary atelectasis, prolonged length of hospital stay, and ICU stay. Our results are similar to the results from the study conducted by Mungan I et al [45].

There have been various studies in the literature investigating the role of PLR and NLR in predicting postoperative complications and they have used different formulas to calculate PLR. Also, various cut-off points have been recommended for the PLR (ranging between 0.66 and 0.44) and NLR (ranging between 3 and 5) in these studies [36,46]. We used the method of calculating PLR as described by Inaoka et al [38]. In our study the specificities of NLR and PLR for predicting complications were high, however, the sensitivities decreased the power of the analysis.

The NLR and PLR are simple biochemical parameters that can be determined in every hospital without adding extra cost burden to the patient. There have been several studies demonstrating the prognostic value of NLR and PLR in patients with upper GI malignancies [46,47]. However, there has been limited research on the influence of preoperative NLR and PLR on postoperative complications in patients undergoing surgery for gastric and esophageal malignancies. According to our study, surgeons can provide precise informed consent information and identify patients at high risk of developing postoperative complications using NLR and PLR as a tool. This will help to tailor the perioperative care as an attempt to ultimately decrease postoperative complications for gastric and esophageal cancer patients undergoing surgery.

Various prediction models such as the Surgical Risk Preoperative Assessment System (SURPAS) and the Physiologic and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) have been used in the preoperative setting in clinical practice [48,49]. Our results suggest that the NLR and PLR can at least become valuable parameters of these scoring systems for the assessment of surgical risk in patients.

It is currently uncertain how an elevated NLR (neutrophil-to-lymphocyte ratio) correlates with a higher occurrence of complications following surgery. One possible explanation for this is that an increased NLR signifies an increased neutrophil count (systemic inflammation) and a decreased lymphocyte count (impaired cell-mediated immunity and malnutrition) [44]. These factors act in a synchronized manner to increase the incidence of postoperative complications. It is unclear how a decreased PLR is linked to postoperative infectious complications. A decrease in PLR collectively indicates a lower total white blood cell count, which can result in compromised cell-mediated immunity and malnutrition. It also suggests an increase in platelet count, which can lead to inflammation and a high tendency for micro-vessel thrombosis [20,43]. Over time, the interaction between these intricate factors raises the likelihood of postoperative complications. This study raises an important question. Whether the preoperative modification of NLR and PLR by nutritional supplements and anti-inflammatory treatment will reduce the incidence of adverse postoperative events? Further studies are needed with a large sample size to answer this question.

This study is not without limitations. This study has been conducted at a single center with a small sample size (n=70). Further large-scale studies are required to validate our results.

4. CONCLUSION

The results of this study indicate that the preoperative NLR and PLR are simple and useful predictors of postoperative complications in patients undergoing a gastrectomy or esophagectomy for gastric or esophageal cancers. In the future, the construction of an integrated risk stratification system using the NLR and PLR can help physicians in decision-making and contribute to the informed consent process before performing these major surgeries.

CONSENT

All authors declare that 'written informed consent was obtained from the patient (or other approved parties) for publication of this article. A copy of the written consent is available for review by the Editorial office/Chief Editor/Editorial Board members of this journal.

ETHICAL APPROVAL (WHEREEVER APPLICABLE)

All authors hereby declare that all experiments have been examined and approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

REFERENCES

1. Song S, Ajani JA. The role of microRNAs in cancers of the upper gastrointestinal tract. *Nat Rev Gastroenterol Hepatol*. 2013;10(2):109–18. [10.1038/nrgastro.2012.210](https://doi.org/10.1038/nrgastro.2012.210).
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*. 2021 Feb 4;71(3):209–49. [10.3322/caac.21660](https://doi.org/10.3322/caac.21660)
3. Choksi D, Kolhe KM, Ingle M, Rathi C, Khairnar H, Chauhan SG, et al. Esophageal carcinoma: An epidemiological analysis and study of the time trends over the last 20 years from a single center in India. *Journal of Family Medicine and Primary Care*. 2020 Mar 1;9(3):1695-9. [10.4103/jfmprc.jfmprc_1111_19](https://doi.org/10.4103/jfmprc.jfmprc_1111_19)
4. Brenkman HJ, Haverkamp L, Ruurda JP, et al (2016) Worldwide practice in gastric cancer surgery. *World J Gastroenterol* 22:4041–4048. [10.3748/wjg.v22.i15.4041](https://doi.org/10.3748/wjg.v22.i15.4041)
5. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. *The Lancet*. 2016 Nov;388(10060):2654–64. [10.1016/S0140-6736\(16\)30354-3](https://doi.org/10.1016/S0140-6736(16)30354-3).
6. Kataoka, K., Takeuchi, H., Mizusawa, J., Ando, M., Tsubosa, Y., Koyanagi, K., Daiko, H., Matsuda, S., Nakamura, K., Kato, K., Kitagawa, Y. and Japan Esophageal Oncology Group/Japan Clinical Oncology Group (2016). A randomized Phase III trial of thoracoscopic versus open esophagectomy for thoracic esophageal cancer: Japan Clinical Oncology Group Study JCOG1409. *Japanese Journal of Clinical Oncology*, 46(2), pp.174–177. [10.1093/jjco/hyt061](https://doi.org/10.1093/jjco/hyt061)
7. Kurita N, Miyata H, Gotoh M, Shimada M, Imura S, Kimura W, et al. Risk Model for Distal Gastrectomy When Treating Gastric Cancer on the Basis of Data From 33,917 Japanese Patients Collected Using a Nationwide Web-based Data Entry System. *Annals of Surgery*. 2015 Aug;262(2):295–303. [10.1097/SLA.0000000000001127](https://doi.org/10.1097/SLA.0000000000001127)
8. Kanda M, Tanaka C, Kobayashi D, Mizuno A, Tanaka Y, Takami H, et al. Proposal of the Coagulation Score as a Predictor for Short-Term and Long-Term Outcomes of Patients with Resectable Gastric Cancer. *Annals of Surgical Oncology*. 2017 Feb 1;24(2):502–9. [10.1245/s10434-016-5544-1](https://doi.org/10.1245/s10434-016-5544-1)
9. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DSJ, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. *European Journal of Cancer (Oxford, England: 1990)*. 2011 Nov 1;47(17):2633–41. [10.1016/j.ejca.2011.03.028](https://doi.org/10.1016/j.ejca.2011.03.028)
10. Proctor MJ, Talwar D, Balmar SM, O'Reilly DSJ, Foulis AK, Horgan PG, et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. *British Journal of Cancer*. 2010 Sep 7;103(6):870–6. [10.1038/sj.bjc.6605855](https://doi.org/10.1038/sj.bjc.6605855)
11. Orditura M, Galizia G, Diana A, Saccone C, Cobellis L, Ventriglia J, et al. Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. *ESMO open*. 2016;1(2):e000038. [10.1136/esmoopen-2016-000038](https://doi.org/10.1136/esmoopen-2016-000038).
12. Miyazaki T, Sakai M, Sohda M, Tanaka N, Yokobori T, Motegi Y, et al. Prognostic significance of inflammatory and nutritional parameters in patients with esophageal cancer. *Anticancer Res*. 2016;36(12):6557–62. [10.21873/anticancer.11259](https://doi.org/10.21873/anticancer.11259).
13. Zhang H, Zhang L, Cheng ZM, Shi B, Yin Y, Zhu J, et al. Prognostic Significance of Combination of Preoperative Platelet Count and Neutrophil-Lymphocyte Ratio (COP-NLR) in Patients with Non-Small Cell Lung Cancer: Based on a Large Cohort Study. 2015 May 7;10(5):e0126496–6. [10.1371/journal.pone.0126496](https://doi.org/10.1371/journal.pone.0126496).
14. Li S, Xu X, Liang D, Tian G, Song S, He Y. [Prognostic value of blood neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with gastric cancer]. *ZhonghuaZhong Liu Za Zhi [Chinese Journal of Oncology]*. 2014 Dec 1;36(12):910–5. [10.3389/fonc.2020.00841](https://doi.org/10.3389/fonc.2020.00841)

15. Mori M, Shuto K, Kosugi C, Narushima K, Hayashi H, Matsubara H, et al. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer. *BMC Cancer*. 2018 Dec;18(1). 10.1186/s12885-018-5171-2.
16. Saito H, Kono Y, Murakami Y, Shishido Y, Kuroda H, Matsunaga T, et al. Prognostic Significance of Platelet-Based Inflammatory Indicators in Patients with Gastric Cancer. *World Journal of Surgery*. 2018 Aug 1;42(8):2542–50. 10.1007/s00268-018-4527-8.
17. Aoyama T, Ju M, Komori K, Takahashi H, Tamagawa A, Onodera A, et al. The Platelet-to-Lymphocyte Ratio Is an Independent Prognostic Factor for Patients With Esophageal Cancer Who Receive Curative Treatment. 2022 Jan 1;36(4):1916–22. 10.21873/invivo.12912
18. Sakin A. Prognostic significance of neutrophil to lymphocyte ratio in esophageal squamous cell carcinoma. *Northern Clinics of Istanbul*. 2020;8(5):435. 10.14744/nci.2020.63004
19. Moyes LH, Leitch EF, McKee RF, Anderson JH, Horgan PG, McMillan DC. Preoperative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer. *British Journal of Cancer*. 2009 Mar 24;100(8):1236–9. 10.1038/sj.bjc.6604997
20. Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic Value of PLR in Various Cancers: A Meta-Analysis. Scheurer M, editor. *PLoS ONE*. 2014 Jun 26;9(6):e101119. 10.1371/journal.pone.0101119
21. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo Classification of Surgical Complications. *Annals of Surgery*. 2009 Aug;250(2):187–96. 10.1097/SLA.0b013e3181b13ca2
22. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging: The Eighth Edition AJCC Cancer Staging Manual. *CA Cancer J Clin*. 2017;67(2):93–9. 10.3322/caac.21388
23. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. *Surgery*. 2017 Mar;161(3):584–91. 10.1016/j.surg.2016.11.014
24. Kieninger AN, Lipsett PA. Hospital-Acquired Pneumonia: Pathophysiology, Diagnosis, and Treatment. *Surgical Clinics of North America*. 2009 Apr 1;89(2):439–61. 10.1016/j.suc.2008.11.001.
25. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *American journal of respiratory and critical care medicine*. 2005;171(4):388–416. 10.1164/rccm.200405-644ST.
26. Strobel O, Brangs S, Hinz U, Pausch T, Hüttner FJ, Diener MK, et al. Incidence, risk factors and clinical implications of chyle leak after pancreatic surgery. *The British Journal of Surgery*. 2017 Jan 1;104(1):108–17. 10.1002/bjs.10316
27. Takahashi R, Ohashi M, Hiki N, Makuuchi R, Ida S, Kumagai K, et al. Risk factors and prognosis of gastric stasis, a crucial problem after laparoscopic pylorus-preserving gastrectomy for early middle-third gastric cancer. *Gastric Cancer*. 2020 Jan 8;23(4):707–15. 10.1007/s10120-019-01037-4.
28. Sgambato A, Cittadini A. Inflammation and cancer: a multifaceted link. *Eur Rev Med Pharmacol Sci*. 2010;14(4):263–8.
29. Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. *Gastroenterology*. 2010;138(6):2101–14. 10.1053/j.gastro.2010.01.058.
30. Brown DJ, Milroy R, Preston T, McMillan DC. The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. *J Clin Pathology*. 2007;60(6):705–8. 10.1136/jcp.2005.033217.
31. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. *Ann Surgery*. 2007;246(6):1047–51. 10.1097/SLA.0b013e3181454171.
32. Kobayashi T, Teruya M, Kishiki T, Endo D, Takenaka Y, Tanaka H, Miki K, Kobayashi K, Morita K. Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. *Surgery*. 2008;144(5): 729–35. 10.1016/j.surg.2008.08.015
33. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. *Critical reviews in oncology/hematology*. 2013;88(1): 218–30. 10.1016/j.critrevonc.2013.03.010.
34. Maruyama Y, Inoue K, Mori K, Gorai K, Shimamoto R, Onitsuka T, Iguchi H, Okazaki M, Nakagawa M. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as predictors of wound healing failure in head and neck reconstruction. *Actaoto-laryngologica*. 2017;137(1):106–10. 10.3892/mco.2018.1698
35. Vulliamy P, McCluney S, Mukherjee S, Ashby L, Amalesh T. Postoperative elevation of the neutrophil: lymphocyte ratio predicts complications following esophageal resection. *World journal of surgery*. 2016;40(6):1397–403. 10.1007/s00268-016-3427-z.

36. Dionigi R, Dominioni L, Benevento A, Giudice G, Cuffari S, Bordone N, et al. Effects of surgical trauma of laparoscopic vs. open cholecystectomy. *Hepatogastroenterology*;41(5):471–6
37. Braga M, Vignali A, Zuliani W, Radaelli G, Gianotti L, Martani C, et al. Metabolic and functional results after laparoscopic colorectal surgery: A randomized, controlled trial. *Dis Colon Rectum* [Internet]. 2002 [cited 2023 Feb 17];45(8):1070–7. 10.1007/s10350-004-6362-2.
38. Inaoka K, Kanda M, Uda H, Tanaka Y, Tanaka C, Kobayashi D, et al. Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer. *World J Gastroenterol* [Internet]. 2017 [cited 2023 Feb 17];23(14):2519. 10.3748/wjg.v23.i14.2519.
39. Kanda M, Mizuno A, Tanaka C, Kobayashi D, Fujiwara M, Iwata N, Hayashi M, Yamada S, Nakayama G, Fujii T, et al. Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer. *Medicine (Baltimore)* 2016;95:e3781. 10.1097/MD.0000000000003781
40. Pang W, Lou N, Jin C, Hu C, Arvine C, Zhu G, Shen X. Combination of preoperative platelet/lymphocyte and neutrophil/lymphocyte rates and tumor-related factors to predict lymph node metastasis in patients with gastric cancer. *Eur J GastroenterolHepatol*. 2016;28:493–502. 10.1097/MEG.000000000000563
41. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Šeruga B, Ocana A, Tannock IF, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *Cancer Epidemiol Prevent Biomarkers*. 2014;23(7):1204. 10.1158/1055-9965.EPI-14-0146
42. Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma. *World J Surg*. 2015;39:1501–1509. 10.1007/s00268-015-2982-z.
43. Kim EY, Lee JW, Yoo HM, Park CH, Song KY. The Platelet-to-Lymphocyte Ratio Versus Neutrophil-to-Lymphocyte Ratio: Which is Better as a Prognostic Factor in Gastric Cancer? *Ann SurgOncol*. 2015;22:4363–4370. 10.1245/s10434-015-4518-z
44. Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR in various cancers: A meta-analysis. *PLoS One* [Internet]. 2014;9(6):e101119. 10.1371/journal.pone.0101119.
45. Mungan İ, Dicle ÇB, Bektaş Ş, Sari S, Yamanyar S, Çavuş M, et al. Does the preoperative platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio predict morbidity after gastrectomy for gastric cancer? *Military Medical Research*. 2020 Feb 29;7(1). 10.1186/s40779-020-00234-y.
46. Zhang Y, Lu JJ, Du YP, Feng CX, Wang LQ, Chen MB. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer. *Medicine*. 2018;97(12):e0144. 10.1097/MD.0000000000010144.
47. Xie X, Luo KJ ., Hu Y, Wang JY ., Chen J. Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. *Diseases of the Esophagus*. 2014 Nov 19;29(1):79–85. 10.1111/dote.12296.
48. Meguid RA, Bronsert MR, Juarez-Colunga E, Hammermeister KE, Henderson WG. Surgical Risk Preoperative Assessment System (SURPAS): III. Accurate Preoperative Prediction of 8 Adverse Outcomes Using 8 Predictor Variables. *Ann Surg*. 2016;264:23–31. 10.1097/SLA.0000000000001678.
49. Chen T, Wang H, Wang H, Song Y, Li X, Wang J. POSSUM and P-POSSUM as predictors of postoperative morbidity and mortality in patients undergoing hepato-biliary-pancreatic surgery: a meta-analysis. *Ann SurgOncol*. 2013;20:2501–2510. 10.1245/s10434-013-2893-x.

ABBREVIATIONS

PLR: Platelet-lymphocyte ratio; NLR: Neutrophil-lymphocyte ratio; PNI: Prognostic nutritional index; SURPAS: Surgical Risk Preoperative Assessment System; POSSUM: Physiologic and Operative Severity Score for the enUmeration of Mortality and morbidity; CA: Carcinoma; PRBC: Packed red blood cell; TNM: Tumor Node Metastasis; AJCC: American Joint Committee on Cancer; GIST: Gastrointestinal stromal tumor; BMI: Body mass index; ICU: Intensive care unit; GI: Gastrointestinal; NK cell: Natural killer cell; ECOG: European Co-operative Oncology Group; ASA: American Society of Anaesthesiology; CI: Confidence interval; ROC: Receiver operative characteristic curve; AUC: Area under the curve; SD: Standard deviation